Drug Trial Radar · NCT05862064
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
606
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Jul 1, 2026
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with conventional chemotherapy regimens (dose-intensive epirubicin and cyclophosphamide, sequential paclitaxel, or EC-P) in patients with early-stage high-risk TNBC.
Conditions
- TNBC - Triple-Negative Breast Cancer
Interventions
epirubicin,cyclophosphamide,paclitaxel,CarrelizumabDrug
Conventional chemotherapy in combination with carrelizumab
epirubicin,cyclophosphamide,paclitaxelDrug
Conventional chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- iDFSTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.